


REMARKS

Claims 1-7, 11, 12 and 15 are currently under examination in the present application. Claims 8-10, 13-14 and 16-36 were withdrawn from consideration as drawn to the non-elected invention. Claims 8-10, 13-14 and 16-36 have been cancelled as drawn to the non-elected invention. Claims 1-7, 11, 12 and 15 are allowable. No new matter has been added. Applicants reserve the right to refile this subject matter in a continuation or divisional application filed during the pendency of this application.

The application was objected to for containing nucleotide sequences not in compliance with 37 CFR § 1.821(d). Applicants have amended the specification to include the appropriate sequence identifiers with these nucleotide sequences and have submitted herewith a revised Sequence Listing in paper and Computer Readable Form (CRF) which includes these sequence identifiers and their respective sequences, along with a statement verifying the paper and CRF are the same. Applicants contend that the application is in compliance with 37 CFR § 1.821 through 1.825, and accordingly request withdrawal of the objection.

In view of the foregoing amendments and remarks, Applicants submit that this application is in condition for allowance.

Respectfully submitted,



Camille Jolly-Tornetta, Ph.D.
Registration No. 48,592

RheoGene, Inc.
2650 Eisenhower Avenue
Norristown, PA 19403
Telephone: (610) 650-8734
Fax: (610) 650-8755

Date: January 4, 2006